|

BMS-936558-01 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Nivolumab

Pipeline

Phase 1/2: 1

Top Sponsors

  • Bristol-Myers Squibb1

Indications

  • Carcinoma, Renal Cell1
  • Squamous Cell Carcinoma of Head and Neck1
  • Microsatellite Stable Colorectal Cancer1
  • Gastric/Gastroesophageal Junction Adenocarcinoma1
  • Ovarian Neoplasms1

Clovis, California1 trial

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Community Cancer Institute

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.